Latest "Insception Biosciences Inc" News Stories

00:20 EDT 23rd July 2018 | BioPortfolio

Here are the most relevant search results for "Insception Biosciences Inc" found in our extensive news archives from over 250 global news sources.

More Information about Insception Biosciences Inc on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Insception Biosciences Inc for you to read. Along with our medical data and news we also list Insception Biosciences Inc Clinical Trials, which are updated daily. BioPortfolio also has a large database of Insception Biosciences Inc Companies for you to search.

Showing "Insception Biosciences" News Articles 1–25 of 1,100+

Sunday 22nd July 2018

Global Next Generation Sequencing Informatics Market Segmented by Services Type, Applications and End Users Growth, Trends and Forecasts 2018 2023 [Report Updated: 01032018] Prices from USD $1923

The global next generation sequencing informatics market is expected to register a CAGR of about 22.0% during 20182023 the forecast period. North America is dominating the market, due to the growing demand for NGS informatics product services in the region.Growing Demand for NGS Service and Rising Investment by Key PlayersThe next generation sequencing NGS informatics services have gained popula...

Friday 20th July 2018

Saudi Arabia Hospital Supplies Market Segmented by Durables, Disposables and Reusables Growth, Trends and Forecasts 2018 2023 [Report Updated: 08022018] Prices from USD $3000

The Saudi Arabia hospital supplies market is estimated to register a CAGR of approximately 7% during the forecast period, 2018 to 2023. Hospital medical equipment and supplies include various devices, tools, instruments, and medical consumables that are used in hospitals and healthcare establishments.Increasing Awareness about HospitalAcquired Infections HAIsThe rise in incidences of infections an...

Series A round brings €16mm to Lava Therapeutics

Lava Therapeutics BV raised €16mm ($18.9mm) through its Series A round. Gilde Healthcare and Versant Ventures co-led, with ...

Thursday 19th July 2018

Enochian Biosciences Announces Appointment of Dr. David Hardy to Scientific Advisory Board

LOS ANGELES, July 20, 2018 (GLOBE NEWSWIRE) -- Enochian Biosciences, Inc. (“Enochian”) (OTCQB:ENOB), a biopharmaceutical company focused on the development and commercialization of novel therapies for HIV/AIDS and cancer, announced today the appointment of David Hardy, MD, to its Scientific Advisory Board (SAB).  Dr. W. David Hardy currently serves as Senior Director of Evidence-bas...

Asana starts Phase llb trial of ASN002 for atopic dermatitis

Asana BioSciences has commenced the RADIANT Phase llb trial to investigate the efficacy, safety, tolerability, and pharmacokinetics of ASN002 to...Read More... The post Asana starts Phase llb trial of ASN002 for atopic dermatitis appeared first on Drug Development Technology.

Asana BioSciences Initiates Phase 2b Study of ASN002 in Patients with Moderate-to-Severe Atopic Dermatitis (RADIANT)

Asana BioSciences, a clinical stage biopharmaceutical company focused on discovery and development of novel targeted investigational medicines in Immunology/Inflammation and Oncology, today announced initiation of a Phase 2b study of ASN002, an oral JAK/SYK inhibitor, in patients with moderate-to-severe atopic dermatitis (AD). “I was impressed b...

Pressure BioSciences developing breakthrough processing method for shelf-stable milk, dairy products

The Massachusetts company’s high-pressure Ultra Shear Technology will play a significant role in the preservation of 'clean label' foods and beverages

Avalon GloboCare Launches Avactis Biosciences Subsidiary

Will focus on accelerating commercial activities related to its (CAR)-T technologies

Arcadia Biosciences and Shriram Bioseed Reach Milestone in Developing Extended Shelf Life Tomatoes

-- Non-GM tomato varieties to reduce post-harvest damage and waste -- Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural food ingredient company, and Shriram Bioseed, a leading research and hybrid seed development company, today announced the achievement of a key milestone in developing Extended Shelf Life (ESL) toma

Wednesday 18th July 2018

Locus Bio acquires phage discovery platform from EpiBiome

Locus Biosciences Inc. has acquired EpiBiome Inc.'s high-throughput bacteriophage discovery platform.

Taconic Biosciences and Cyagen Biosciences Announce Strategic Partnership

RENSSELAER, N.Y., July 18, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences and Cyagen Biosciences, global leaders in the generation of custom genetically engineered rodent models and associated services, announced a strategic partnership.  Under the agreement terms, the two companies will combine resources to provide the global scientific community with access to premium custom model design an...

Preclinical data shows promise for potential treatment of chronic lymphocytic leukaemia

Private therapeutics company, Inflection Biosciences, has published preclinical data, demonstrating that its dual mechanism PIM/PI3 kinase inhibitor IBL-202 has promise for the treatment of chronic lymphocytic leukaemia (CLL).

Dr. Chris Surek to join Plastic & Reconstructive Surgery Center

Chris Surek, DO, joins Overland Park office of Dermatology & Skin Cancer Centers KANSAS CITY, Kansas (PRWEB) July 18, 2018 Dr. Chris Surek will begin treating patients at Plastic & Reconstructive Surgery Center, located within Dermatology & Skin Cancer Centers in Overland Park, on July 18. Dr. Surek is a board-eligible plastic surgeon, specializing in aesthetic and cosmetic surgery o...

CRNX, RUBY To Debut On Nasdaq, CLRB On Watch, PULM To Advance Pulmazole In Q4

Today's Daily Dose brings you news about IPOs of Crinetics Pharma and Rubius; secondary offerings of Cara, Oragenics and CytomX, and promising efficacy of Cellectar Biosciences' drug candidate CLR 131 observed in a single patient in a phase II trial.

Tuesday 17th July 2018

Cellectar Biosciences Strong Preliminary Data For Rare Cancer Treatment Is Encouraging

Akers Biosciences Signs a Further Independent Sales Representative Organization for Heparin PF4 Rapid Test Covering Additional 12 States

THOROFARE, N.J.,, July 18, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, announces another agreement with a major Independent Sales Representative (ISR) organization, adding sales and marketing coverage for the Company’s rapid test for heparin-induced thrombocytopenia (HIT...

Catalyst Biosciences Announces Positive Interim Data from a Phase 2/3 Study of Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors

Interim data support goal of significantly reducing annualized bleed rates with daily subcutaneous injections of marzeptacog alfa (activated) Conference call and webcast to be held today, July 18, 2018 at 8:30 a.m. EDT SOUTH SAN FRANCISCO, Calif., July 18, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel...

Avalon GloboCare Announces Plans to Accelerate Commercialization of Proprietary CAR-T Technologies through Launch of Wholly Owned Subsidiary - Avactis Biosciences

FREEHOLD, N.J., July 18, 2018 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (OTCQB:AVCO), a leading global developer of cell-based technologies and therapeutics, announced today that the Company has formed a new wholly owned U.S. subsidiary, Avactis Biosciences, Inc., which will be focused on accelerating commercial activities related to its proprietary Chimeric Antigen Receptor (CAR)-T technolog...

Cellectar Biosciences shares rollercoaster after one patient sees a 94% tumor reduction in its mid-stage trial

The Phase 2 trial of its drug CLR 131 will enroll a total of 80 patients and continue until March 2019


Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: Anmerkungen US15117F3029 Cellectar Biosciences Inc. 17.07.2018 US15117F5008 Cellectar Biosciences Inc. 18.07.2018 Tausch 10:...

Locus Biosciences acquires EpiBiome’s high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics

The post Locus Biosciences acquires EpiBiome’s high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics appeared first on SynBioBeta.

Novel xCELLigence Study of Acinetobacter baumannii Biofilms Receives Award

Doctoral candidate using real-time impedance monitoring to elucidate key biofilm genes awarded a travel grant by ACEA Biosciences SAN DIEGO, Calif. (PRWEB) July 17, 2018 By using the xCELLigence instrument to monitor the attachment and growth of Acinetobacter baumannii in real-time, University of South Florida graduate student Jessie Adams has discovered key genes/proteins that enable this pathog...

Arcus Biosciences Announces Final Safety Results From Phase 1 Trial for AB928 in Healthy Volunteers

- AB928 was safe and well tolerated at all doses evaluated - - Safety and pharmacodynamic data from healthy volunteer trial support selection of dose for evaluation of AB928 in combination with anti-PD-1 therapy in patients - Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer i...

CRISPR-Cas3 Platform Developer Locus Biosciences Acquires EpiBiome Phage Technology

Locus Biosciences, a developer of CRISPR-Cas3-engineered precision antibacterial products, has acquired EpiBiome’s high-throughput bacteriophage phage discovery platform for an undisclosed price, in a deal designed to help the buyer develop a leading presence in CRISPR-engineered phage therapeutics. Locus reasons that it can more rapidly develop products to treat antibiotic-resistant bacteri...

Salveo Capital Announces Investment in PathogenDx

Salveo Capital, an alternative investment firm specializing in the legalized cannabis space, today announced it has acquired a minority equity interest in PathogenDx, a provider of DNA-based pathogen testing kits for the cannabis, botanical, food and agriculture industries. Financial terms of the transaction were not disclosed. Founded in 2014, Pa...

Quick Search


News Quicklinks